KA/EN
Register
Medicines reference
Search
Search
Active substance

Oxytetracycline

Favourites

Tetracycline. Registered in Georgia: 4 veterinary products. Forms: aerosol / spray, solution.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Oxytetracycline
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
25 mg/kg Dog Bacterial Infection By mouth 2 times daily
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Oxycare Tablets 250 mg - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
10 mg/kg Dog, Cat Bacterial Infection Intramuscular / Subcutaneous once daily
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Engemycin 10% DD solution for injection - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
VMD SPC 2024
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Oxtra DD 100 mg/ml solution for injection for cattle, sheep, pigs, horses, dogs and cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2024
50 mg/kg Dog Bacterial Infection
Loading
 By mouth once, as the first dose
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Oxycare Tablets 250 mg - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
Before use

Safety information

Known Contraindications

  • Critical
    Do not use oxytetracycline in patients with hypersensitivity to oxytetracycline or another tetracycline.
  • Critical
    Oxytetracycline crosses the placenta and is not recommended in late pregnancy. Tetracycline deposition can discolor developing teeth, cause enamel hypoplasia and reduced mineralisation, and delay fetal skeletal development. If no alternative exists, use only after a benefit-risk assessment.
  • Warning
    Avoid oxytetracycline in young growing animals because it is deposited in developing teeth and bones and can cause yellow, brown, or grey discoloration and impaired mineralisation.
  • Warning (Dog)
    Do not administer this oxytetracycline formulation intravenously to dogs. Use only a route authorised for the selected product.
  • Warning (Cat)
    Do not administer this oxytetracycline formulation intravenously to cats. Use only a route authorised for the selected product.
  • Caution
    Use oxytetracycline cautiously in hepatic impairment. Hepatic toxicity is a rare adverse effect, and dose reduction may be necessary.
  • Caution
    Use oxytetracycline cautiously in renal impairment; dose reduction may be necessary.

Known Drug Interactions

  • Major warning Oxytetracycline + Benzathine Benzylpenicillin
    Do not give oxytetracycline at the same time as bactericidal antimicrobials such as penicillins or cephalosporins because their antibacterial effects may be antagonistic.
    Recommendation: Do not administer concurrently.
  • Major warning Oxytetracycline + Ceftriaxone
    Do not give oxytetracycline at the same time as bactericidal antimicrobials such as penicillins or cephalosporins because their antibacterial effects may be antagonistic.
    Recommendation: Do not administer concurrently.
  • Major warning Amoxicillin + Oxytetracycline
    Do not give oxytetracycline at the same time as bactericidal antimicrobials such as penicillins or cephalosporins because their antibacterial effects may be antagonistic.
    Recommendation: Do not administer concurrently.
  • Major warning Ampicillin + Oxytetracycline
    Do not give oxytetracycline at the same time as bactericidal antimicrobials such as penicillins or cephalosporins because their antibacterial effects may be antagonistic.
    Recommendation: Do not administer concurrently.
  • Major warning Oxytetracycline + Procaine Benzylpenicillin
    Do not give oxytetracycline at the same time as bactericidal antimicrobials such as penicillins or cephalosporins because their antibacterial effects may be antagonistic.
    Recommendation: Do not administer concurrently.
  • Minor warning Oxytetracycline + Calcium Carbonate
    Divalent and trivalent cations, including magnesium, iron, aluminium, and calcium, can chelate oxytetracycline and reduce its absorption. Do not give it at the same time as milk or antacids.
    Recommendation: Separate this medicine from oral oxytetracycline in time.
  • Minor warning Oxytetracycline + Calcium chloride
    Do not mix oxytetracycline with calcium-containing infusion solutions because they are physically incompatible.
    Recommendation: Do not mix oxytetracycline with lactated Ringer solution or run them through the same line.
  • Minor warning Oxytetracycline + Magnesium Carbonate
    Divalent and trivalent cations, including magnesium, iron, aluminium, and calcium, can chelate oxytetracycline and reduce its absorption. Do not give it at the same time as milk or antacids.
    Recommendation: Separate this medicine from oral oxytetracycline in time.
  • Minor warning Oxytetracycline + Sucralfate
    Divalent and trivalent cations, including magnesium, iron, aluminium, and calcium, can chelate oxytetracycline and reduce its absorption. Do not give it at the same time as milk or antacids.
    Recommendation: Separate this medicine from oral oxytetracycline in time.
Latin name
Oxytetracycline
Georgian name
ოქსიტეტრაციკლინი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
4 of 4 forms
Products
Oxtra, Oxtra LA, Terramycin
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration4

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Oxtra 5%, Solution

50 mg/ml, solution for injection
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Culture- and susceptibility-directed treatment of bacterial infection caused by oxytetracycline-susceptible organisms; not empirical treatment of every syndrome listed in the broad legacy label.
5.3/10
Weak evidence support
vetman assessment

Oxtra

5%, 50 mg/ml, solution for injection
Assessed clinical scopeDog · Culture- and susceptibility-directed treatment of bacterial infection caused by oxytetracycline-susceptible organisms; not empirical treatment of every syndrome listed in the broad legacy label. · Intramuscular
Care settingVeterinary clinic or supervised treatment setting able to confirm the diagnosis, calculate injection volume, use deep IM technique, divide larger volumes among sites and reassess clinical response within 48-72 hours
vetman score 5.3/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · № 000381 · Verified on 15 Oct 2026

A usable labelled dog/cat injectable for selected susceptible bacterial infections, but not a broad empirical default. Its exact dose and composition are transparent and locally authorised, while modern exact-product outcome and pharmacovigilance evidence are limited. Confirm susceptibility where feasible, protect renal/hepatic and growing patients, use deep IM technique and reassess early rather than extending an ineffective course.

Regulatory and scientific credibility6.5/10

The exact 50 mg/ml veterinary presentation has a current Georgian authorisation (000381, valid to 2028-06-30) and an official manufacturer instruction identifying composition, route, dog/cat dose, duration and local-tolerance precautions. It is not currently authorised as this exact strength in the checked EU/EEA, GB or US registers, and no regulator-hosted exact-product dossier or modern independent pharmacovigilance series was located.

Clinical efficacy5.0/10

Oxytetracycline is an established tetracycline with relevant susceptible-organism activity, and the exact label provides a coherent 8-12 mg/kg once-daily IM regimen for 3-5 days. However, its broad syndrome list is not supported by indication-specific modern dog/cat outcome trials, resistance can materially narrow coverage, and no exact-product comparative clinical study was located; culture and current susceptibility should define use.

Safety and tolerability5.0/10

The product is species-labelled and contains lidocaine to reduce injection discomfort, but tetracycline-class hypersensitivity, dysbiosis, hepatic/renal risk, deposition in developing teeth and bone, photosensitivity and superinfection remain relevant. Deep IM administration can cause local irritation, tissue injury and slow absorption with hardening, particularly at higher canine volumes; exact-product dog/cat safety evidence is mainly the label rather than a quantified modern series.

Clinical practicality4.5/10

The ready-to-use solution avoids reconstitution and is dosed once daily, but 0.16-0.24 ml/kg creates a clinically meaningful injection volume, especially in larger dogs. Deep IM technique, daily clinic/supervised administration for 3-5 days, site rotation or volume splitting and response review add treatment burden; concentration must be distinguished from 100 mg/ml immediate and 200 mg/ml depot products.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only for a diagnosed or strongly supported bacterial infection when oxytetracycline susceptibility is plausible; obtain culture and susceptibility whenever feasible. Do not continue an ineffective empirical course merely because the historical label lists many syndromes.
  • Verify the exact 50 mg/ml immediate-release presentation with lidocaine. Do not substitute the 100 mg/ml product volume or the 200 mg/ml long-acting depot: concentration, excipients, dose interval and species evidence differ.
  • Give by deep intramuscular injection only. The exact label reports slow absorption and hardening around the injection site at higher canine doses; divide larger volumes among sites, use aseptic technique and monitor for pain, swelling, tissue injury or abscessation.
  • Do not use with known hypersensitivity to oxytetracycline, another tetracycline or an excipient. Allergic or anaphylactic reactions are possible; stop treatment and provide emergency care for acute facial swelling, dyspnoea, collapse or other systemic reaction.
  • Avoid or use only after a documented benefit-risk decision in renal or hepatic impairment, dehydration, hypovolaemia or severe systemic illness. Tetracyclines can increase BUN and cause renal/hepatic toxicity; obtain baseline values and monitor clinically relevant change.
  • Tetracyclines deposit in developing teeth and bone. Avoid late pregnancy and use in growing/neonatal animals unless the expected benefit clearly outweighs tooth discolouration, enamel/bone effects and the unestablished exact-product reproductive risk.
  • Review concurrent antimicrobials. The applicable oxytetracycline labels advise against simultaneous bactericidal penicillins or cephalosporins; do not combine automatically, and let culture, infection site and a deliberate antimicrobial plan govern any exception.
  • Do not dilute or mix this product with calcium-containing solutions. Verify physical and chemical compatibility before any admixture; use a separate syringe and administration site when compatibility has not been established.
  • Monitor response within 48-72 hours and reassess diagnosis, source control and susceptibility if improvement is absent. Broad-spectrum exposure can select resistant bacteria and permit fungal, yeast or nonsusceptible bacterial superinfection.
  • The exact dog/cat label supports 0.16-0.24 ml/kg IM once daily for 3-5 days. Calculate milligrams and millilitres independently, account for lidocaine exposure, and do not exceed the labelled concentration-specific range without a separately sourced protocol.
Assessment sources
  1. Oxtra 5% official instruction2017
  2. Oxtra GE register audit2026
  3. VMD SPC 20242024
  4. MSD tetracyclines2026
  5. EMA AMEG 20252025
  6. Oxtra LA EU UPD2026
  7. Canine LA oxytetracycline PK2001
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Culture- and susceptibility-directed treatment of bacterial infection caused by oxytetracycline-susceptible organisms; not empirical treatment of every syndrome listed in the broad legacy label.
5.3/10
Weak evidence support
vetman assessment

Oxtra

5%, 50 mg/ml, solution for injection
Assessed clinical scopeCat · Culture- and susceptibility-directed treatment of bacterial infection caused by oxytetracycline-susceptible organisms; not empirical treatment of every syndrome listed in the broad legacy label. · Intramuscular
Care settingVeterinary clinic or supervised treatment setting able to confirm the diagnosis, calculate injection volume, use deep IM technique, divide larger volumes among sites and reassess clinical response within 48-72 hours
vetman score 5.3/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · № 000381 · Verified on 15 Oct 2026

A usable labelled dog/cat injectable for selected susceptible bacterial infections, but not a broad empirical default. Its exact dose and composition are transparent and locally authorised, while modern exact-product outcome and pharmacovigilance evidence are limited. Confirm susceptibility where feasible, protect renal/hepatic and growing patients, use deep IM technique and reassess early rather than extending an ineffective course.

Regulatory and scientific credibility6.5/10

The exact 50 mg/ml veterinary presentation has a current Georgian authorisation (000381, valid to 2028-06-30) and an official manufacturer instruction identifying composition, route, dog/cat dose, duration and local-tolerance precautions. It is not currently authorised as this exact strength in the checked EU/EEA, GB or US registers, and no regulator-hosted exact-product dossier or modern independent pharmacovigilance series was located.

Clinical efficacy5.0/10

Oxytetracycline is an established tetracycline with relevant susceptible-organism activity, and the exact label provides a coherent 8-12 mg/kg once-daily IM regimen for 3-5 days. However, its broad syndrome list is not supported by indication-specific modern dog/cat outcome trials, resistance can materially narrow coverage, and no exact-product comparative clinical study was located; culture and current susceptibility should define use.

Safety and tolerability5.0/10

The product is species-labelled and contains lidocaine to reduce injection discomfort, but tetracycline-class hypersensitivity, dysbiosis, hepatic/renal risk, deposition in developing teeth and bone, photosensitivity and superinfection remain relevant. Deep IM administration can cause local irritation, tissue injury and slow absorption with hardening, particularly at higher canine volumes; exact-product dog/cat safety evidence is mainly the label rather than a quantified modern series.

Clinical practicality4.5/10

The ready-to-use solution avoids reconstitution and is dosed once daily, but 0.16-0.24 ml/kg creates a clinically meaningful injection volume, especially in larger dogs. Deep IM technique, daily clinic/supervised administration for 3-5 days, site rotation or volume splitting and response review add treatment burden; concentration must be distinguished from 100 mg/ml immediate and 200 mg/ml depot products.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only for a diagnosed or strongly supported bacterial infection when oxytetracycline susceptibility is plausible; obtain culture and susceptibility whenever feasible. Do not continue an ineffective empirical course merely because the historical label lists many syndromes.
  • Verify the exact 50 mg/ml immediate-release presentation with lidocaine. Do not substitute the 100 mg/ml product volume or the 200 mg/ml long-acting depot: concentration, excipients, dose interval and species evidence differ.
  • Give by deep intramuscular injection only. The exact label reports slow absorption and hardening around the injection site at higher canine doses; divide larger volumes among sites, use aseptic technique and monitor for pain, swelling, tissue injury or abscessation.
  • Do not use with known hypersensitivity to oxytetracycline, another tetracycline or an excipient. Allergic or anaphylactic reactions are possible; stop treatment and provide emergency care for acute facial swelling, dyspnoea, collapse or other systemic reaction.
  • Avoid or use only after a documented benefit-risk decision in renal or hepatic impairment, dehydration, hypovolaemia or severe systemic illness. Tetracyclines can increase BUN and cause renal/hepatic toxicity; obtain baseline values and monitor clinically relevant change.
  • Tetracyclines deposit in developing teeth and bone. Avoid late pregnancy and use in growing/neonatal animals unless the expected benefit clearly outweighs tooth discolouration, enamel/bone effects and the unestablished exact-product reproductive risk.
  • Review concurrent antimicrobials. The applicable oxytetracycline labels advise against simultaneous bactericidal penicillins or cephalosporins; do not combine automatically, and let culture, infection site and a deliberate antimicrobial plan govern any exception.
  • Do not dilute or mix this product with calcium-containing solutions. Verify physical and chemical compatibility before any admixture; use a separate syringe and administration site when compatibility has not been established.
  • Monitor response within 48-72 hours and reassess diagnosis, source control and susceptibility if improvement is absent. Broad-spectrum exposure can select resistant bacteria and permit fungal, yeast or nonsusceptible bacterial superinfection.
  • The exact dog/cat label supports 0.16-0.24 ml/kg IM once daily for 3-5 days. Calculate milligrams and millilitres independently, account for lidocaine exposure, and do not exceed the labelled concentration-specific range without a separately sourced protocol.
Assessment sources
  1. Oxtra 5% official instruction2017
  2. Oxtra GE register audit2026
  3. VMD SPC 20242024
  4. MSD tetracyclines2026
  5. EMA AMEG 20252025
  6. Oxtra LA EU UPD2026
  7. Canine LA oxytetracycline PK2001
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Oxytetracycline50 mg/ml
Formulation Type
Solution
Administration route
Intramuscular
Manufacturer
Fatro von Franken · Argentina
Manufacturer (register)
FATRO S.p.A., Italy
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 866, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
In force until 30 Jun 2028
Veterinary (National Food Agency)
In the register: ოქსტრა
№ 000381
Verified on: 15 Oct 2026
 EU No
Verified on: 15 Oct 2026
 UK No
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Oxtra 10%, Solution

100 mg/ml, solution for injection
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Potential treatment of a confirmed oxytetracycline-susceptible bacterial infection using the exact Georgian Oxtra 10% presentation
Not rateable
No numerical score assigned
vetman assessment

Oxtra

10%, 100 mg/ml, solution for injection
Assessed clinical scopeDog · Potential treatment of a confirmed oxytetracycline-susceptible bacterial infection using the exact Georgian Oxtra 10% presentation ·
Care settingVeterinarian-directed antimicrobial treatment only after exact Georgian label verification, diagnosis and susceptibility-led product selection
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: Yes, veterinary · № 1-03/45 · Verified on 23 Oct 2026
Not rateable

The Georgian register confirms Fatro Oxtra 10%, a 100 ml injectable solution whose composition cell prints oxytetracycline hydrochloride 100 mg without a denominator, and lists dogs as a target species. No exact public label establishes canine route, dose, indication details, excipients or safety. Oxtra DD and the Cyprus-authorised Oxtra 10% are different authorisation identities; old canine class PK and comparator labels cannot resolve that collision, so numerical axes would be invented.

The local registration and nominal product identity are real, but the catalogue currently merges clinical instructions from two different Fatro presentations. Until the Georgian authorised leaflet/SPC links exact formulation, route, regimen and safety to authorisation 1-03/45, publish no dog/cat dose and no numerical product score.

Important safety and use flags

  • No exact public Georgian clinical label was found. NFA verifies registration, strength, pack, manufacturer and target species but does not independently establish dog/cat route, dose, indication details or safety.
  • Do not transfer the Oxtra DD 10 mg/kg SC/IM regimen. Oxtra DD is a current, transparent Fatro comparator with a different trade and authorisation identity; matching manufacturer and nominal strength are not proof of formulation equivalence.
  • Do not transfer the EU Oxtra 10% regimen. Its 92.7 mg/ml oxytetracycline is explicitly equivalent to 100 mg/ml hydrochloride, but it is a separate authorisation for cattle, horses, pigs and sheep, not the Georgian dog/cat product.
  • No dog/cat dose is published here. Obtain the authorised Georgian package leaflet/SPC and link it to authorisation 1-03/45 before using this exact presentation.
  • Use an antimicrobial only for a diagnosed bacterial infection and base selection on pathogen identification and susceptibility where feasible. Broad legacy spectrum does not make oxytetracycline an empirical default.
  • Tetracycline hypersensitivity, hepatic or renal impairment, pregnancy and growth-phase tooth/bone effects are important class/comparator concerns; exact Georgian warnings and incidence remain unverified.
  • Injection-site irritation, tissue injury, photosensitivity, delayed healing and hypersensitivity are plausible comparator risks. Route, volume, repeat-site handling and local tolerance cannot be assumed for this exact product.
  • Until the exact Georgian instruction is obtained, do not mix, dilute or combine this product with another injectable at one site; those restrictions are established for the comparator, while this formulation’s compatibility is unverified.
  • Concurrent penicillins or cephalosporins and polyvalent-cation products require exact-label review. The Oxtra DD interaction text is a comparator warning, not proof that every formulation has identical compatibility.
  • Current exact Georgian price/availability and a defensible dog/cat regimen are both unavailable, so full-course cost and vial waste are not assessed.
Assessment sources
  1. Oxtra 10% GE register2026
  2. Oxtra DD VMD product record2025
  3. Oxtra DD VMD label2025
  4. Oxtra DD EU UPD2026
  5. Oxtra 10% 92.7 EU UPD2026
  6. EMA AMEG 20252025
  7. MSD tetracyclines2026
  8. Canine oxytetracycline PK1978
  9. Canine oxytetracycline PBPK2015
Assessed: 23 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Cat Potential treatment of a confirmed oxytetracycline-susceptible bacterial infection using the exact Georgian Oxtra 10% presentation
Not rateable
No numerical score assigned
vetman assessment

Oxtra

10%, 100 mg/ml, solution for injection
Assessed clinical scopeCat · Potential treatment of a confirmed oxytetracycline-susceptible bacterial infection using the exact Georgian Oxtra 10% presentation ·
Care settingVeterinarian-directed antimicrobial treatment only after exact Georgian label verification, diagnosis and susceptibility-led product selection
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: Yes, veterinary · № 1-03/45 · Verified on 23 Oct 2026
Not rateable

The Georgian register confirms Fatro Oxtra 10%, a 100 ml injectable solution whose composition cell prints oxytetracycline hydrochloride 100 mg without a denominator, and lists cats as a target species. No exact public label establishes feline route, dose, indication details, excipients or safety. Oxtra DD is a different authorisation identity, and the feline observational cohort did not identify this product; numerical axes would therefore be invented.

The local registration and nominal product identity are real, but the catalogue currently merges clinical instructions from two different Fatro presentations. Until the Georgian authorised leaflet/SPC links exact formulation, route, regimen and safety to authorisation 1-03/45, publish no dog/cat dose and no numerical product score.

Important safety and use flags

  • No exact public Georgian clinical label was found. NFA verifies registration, strength, pack, manufacturer and target species but does not independently establish dog/cat route, dose, indication details or safety.
  • Do not transfer the Oxtra DD 10 mg/kg SC/IM regimen. Oxtra DD is a current, transparent Fatro comparator with a different trade and authorisation identity; matching manufacturer and nominal strength are not proof of formulation equivalence.
  • Do not transfer the EU Oxtra 10% regimen. Its 92.7 mg/ml oxytetracycline is explicitly equivalent to 100 mg/ml hydrochloride, but it is a separate authorisation for cattle, horses, pigs and sheep, not the Georgian dog/cat product.
  • No dog/cat dose is published here. Obtain the authorised Georgian package leaflet/SPC and link it to authorisation 1-03/45 before using this exact presentation.
  • Use an antimicrobial only for a diagnosed bacterial infection and base selection on pathogen identification and susceptibility where feasible. Broad legacy spectrum does not make oxytetracycline an empirical default.
  • Tetracycline hypersensitivity, hepatic or renal impairment, pregnancy and growth-phase tooth/bone effects are important class/comparator concerns; exact Georgian warnings and incidence remain unverified.
  • Injection-site irritation, tissue injury, photosensitivity, delayed healing and hypersensitivity are plausible comparator risks. Route, volume, repeat-site handling and local tolerance cannot be assumed for this exact product.
  • Until the exact Georgian instruction is obtained, do not mix, dilute or combine this product with another injectable at one site; those restrictions are established for the comparator, while this formulation’s compatibility is unverified.
  • Concurrent penicillins or cephalosporins and polyvalent-cation products require exact-label review. The Oxtra DD interaction text is a comparator warning, not proof that every formulation has identical compatibility.
  • Current exact Georgian price/availability and a defensible dog/cat regimen are both unavailable, so full-course cost and vial waste are not assessed.
Assessment sources
  1. Oxtra 10% GE register2026
  2. Oxtra DD VMD product record2025
  3. Oxtra DD VMD label2025
  4. Oxtra DD EU UPD2026
  5. Oxtra 10% 92.7 EU UPD2026
  6. EMA AMEG 20252025
  7. MSD tetracyclines2026
  8. Feline Mycoplasma treatment cohort2021
Assessed: 23 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
Oxytetracycline100 mg/ml
Formulation Type
Solution
Manufacturer
Fatro S.p.A. · Italy
Manufacturer (register)
FATRO S.p.A. Ltd, Italy
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 37, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ოქსტრა 10%
№ 1-03/45
Verified on: 23 Oct 2026
 EU Not confirmed
Verified on: 23 Oct 2026
 UK Not confirmed
Verified on: 23 Oct 2026
 US Not confirmed
Verified on: 23 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified No dog/cat dose or administration route is published for this exact Georgian presentation. Do not transfer the Oxtra DD 10 mg/kg SC/IM regimen, the EU Oxtra 10% 92.7 mg/ml food-animal regimen, the Oxtra 5% dose or a long-acting formulation. Obtain the authorised Georgian package leaflet/SPC before clinical use.

Oxtra LA 200 mg/ml, Solution

long-acting solution for injection
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Proposed off-label long-acting IM oxytetracycline treatment in dogs or cats; the exact product has no authorised dog/cat indication or regimen.
Not rateable
No numerical score assigned
vetman assessment

Oxtra LA

200 mg/ml, long-acting solution for injection
Assessed clinical scopeDog · Proposed off-label long-acting IM oxytetracycline treatment in dogs or cats; the exact product has no authorised dog/cat indication or regimen. · Intramuscular
Care settingNot an established dog/cat care pathway; any exceptional proposed use would require infectious-disease justification, exact formulation review, informed consent and planned monitoring rather than extrapolation from food-animal dosing
vetman score Not rateable No numerical score assigned
Evidence confidence: Medium Georgia: Yes, veterinary · № 1-03/41 · Verified on 15 Oct 2026 Off-label use
Not rateable

A responsible numerical score cannot be calculated for this exact canine use. Current exact-product regulatory material identifies 200 mg/ml long-acting Oxtra as an IM product for cattle, buffalo, sheep, goats, pigs and broilers, with no dog indication or regimen. One old study described pharmacokinetics of an unspecified long-acting oxytetracycline formulation at 20 mg/kg IM in healthy and Ehrlichia-infected dogs, but it did not establish equivalence to this depot, a validated clinical regimen, comparative efficacy or exact-product safety. Depot kinetics are formulation-specific, so the 5% or 100 mg/ml dog dose cannot be transferred.

The product itself is transparent and currently authorised for its listed livestock/poultry species, but that does not make it a scoreable dog/cat treatment. The correct small-animal conclusion is not a low score: it is that the exact depot lacks the species-specific dose, efficacy and safety bridge required for numerical assessment.

Important safety and use flags

  • Use only for a diagnosed or strongly supported bacterial infection when oxytetracycline susceptibility is plausible; obtain culture and susceptibility whenever feasible. Do not continue an ineffective empirical course merely because the historical label lists many syndromes.
  • This is the 200 mg/ml long-acting depot, not Oxtra 5% or Oxtra DD 100 mg/ml. Do not derive a dog/cat volume from another strength or assume that equal milligrams produce equivalent exposure; depot release is formulation-specific.
  • The exact product is authorised intramuscularly for listed livestock/poultry species, not dogs or cats. A dog/cat injection site, maximum site volume, redosing interval and reversibility of depot exposure are not established.
  • Do not use with known hypersensitivity to oxytetracycline, another tetracycline or an excipient. Allergic or anaphylactic reactions are possible; stop treatment and provide emergency care for acute facial swelling, dyspnoea, collapse or other systemic reaction.
  • Avoid or use only after a documented benefit-risk decision in renal or hepatic impairment, dehydration, hypovolaemia or severe systemic illness. Tetracyclines can increase BUN and cause renal/hepatic toxicity; obtain baseline values and monitor clinically relevant change.
  • Tetracyclines deposit in developing teeth and bone. Avoid late pregnancy and use in growing/neonatal animals unless the expected benefit clearly outweighs tooth discolouration, enamel/bone effects and the unestablished exact-product reproductive risk.
  • Review concurrent antimicrobials. The applicable oxytetracycline labels advise against simultaneous bactericidal penicillins or cephalosporins; do not combine automatically, and let culture, infection site and a deliberate antimicrobial plan govern any exception.
  • Do not dilute or mix this product with calcium-containing solutions. Verify physical and chemical compatibility before any admixture; use a separate syringe and administration site when compatibility has not been established.
  • Monitor response within 48-72 hours and reassess diagnosis, source control and susceptibility if improvement is absent. Broad-spectrum exposure can select resistant bacteria and permit fungal, yeast or nonsusceptible bacterial superinfection.
  • No dog or cat dose is established for exact Oxtra LA. Do not use the food-animal 20-30 mg/kg depot regimen, the old unspecified canine PK dose, or the immediate-release 5%/10% schedule as a substitute for missing species-specific evidence.
Assessment sources
  1. Oxtra LA EU UPD2026
  2. Oxtra LA SmPC2026
  3. Oxtra GE register audit2026
  4. Oxtra 5% official instruction2017
  5. VMD SPC 20242024
  6. MSD tetracyclines2026
  7. Canine LA oxytetracycline PK2001
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Cat Proposed off-label long-acting IM oxytetracycline treatment in dogs or cats; the exact product has no authorised dog/cat indication or regimen.
Not rateable
No numerical score assigned
vetman assessment

Oxtra LA

200 mg/ml, long-acting solution for injection
Assessed clinical scopeCat · Proposed off-label long-acting IM oxytetracycline treatment in dogs or cats; the exact product has no authorised dog/cat indication or regimen. · Intramuscular
Care settingNot an established dog/cat care pathway; any exceptional proposed use would require infectious-disease justification, exact formulation review, informed consent and planned monitoring rather than extrapolation from food-animal dosing
vetman score Not rateable No numerical score assigned
Evidence confidence: Medium Georgia: Yes, veterinary · № 1-03/41 · Verified on 15 Oct 2026 Off-label use
Not rateable

A responsible numerical score cannot be calculated for this exact feline use. Current exact-product regulatory material identifies 200 mg/ml long-acting Oxtra as an IM product for food animals and broilers, with no cat indication or regimen. No applicable feline pharmacokinetic, clinical-outcome or exact-product safety study was located. Depot kinetics are formulation-specific, so neither the 5% immediate-release label nor a dog or food-animal long-acting regimen can supply the missing feline dose and benefit-risk evidence.

The product itself is transparent and currently authorised for its listed livestock/poultry species, but that does not make it a scoreable dog/cat treatment. The correct small-animal conclusion is not a low score: it is that the exact depot lacks the species-specific dose, efficacy and safety bridge required for numerical assessment.

Important safety and use flags

  • Use only for a diagnosed or strongly supported bacterial infection when oxytetracycline susceptibility is plausible; obtain culture and susceptibility whenever feasible. Do not continue an ineffective empirical course merely because the historical label lists many syndromes.
  • This is the 200 mg/ml long-acting depot, not Oxtra 5% or Oxtra DD 100 mg/ml. Do not derive a dog/cat volume from another strength or assume that equal milligrams produce equivalent exposure; depot release is formulation-specific.
  • The exact product is authorised intramuscularly for listed livestock/poultry species, not dogs or cats. A dog/cat injection site, maximum site volume, redosing interval and reversibility of depot exposure are not established.
  • Do not use with known hypersensitivity to oxytetracycline, another tetracycline or an excipient. Allergic or anaphylactic reactions are possible; stop treatment and provide emergency care for acute facial swelling, dyspnoea, collapse or other systemic reaction.
  • Avoid or use only after a documented benefit-risk decision in renal or hepatic impairment, dehydration, hypovolaemia or severe systemic illness. Tetracyclines can increase BUN and cause renal/hepatic toxicity; obtain baseline values and monitor clinically relevant change.
  • Tetracyclines deposit in developing teeth and bone. Avoid late pregnancy and use in growing/neonatal animals unless the expected benefit clearly outweighs tooth discolouration, enamel/bone effects and the unestablished exact-product reproductive risk.
  • Review concurrent antimicrobials. The applicable oxytetracycline labels advise against simultaneous bactericidal penicillins or cephalosporins; do not combine automatically, and let culture, infection site and a deliberate antimicrobial plan govern any exception.
  • Do not dilute or mix this product with calcium-containing solutions. Verify physical and chemical compatibility before any admixture; use a separate syringe and administration site when compatibility has not been established.
  • Monitor response within 48-72 hours and reassess diagnosis, source control and susceptibility if improvement is absent. Broad-spectrum exposure can select resistant bacteria and permit fungal, yeast or nonsusceptible bacterial superinfection.
  • No dog or cat dose is established for exact Oxtra LA. Do not use the food-animal 20-30 mg/kg depot regimen, the old unspecified canine PK dose, or the immediate-release 5%/10% schedule as a substitute for missing species-specific evidence.
Assessment sources
  1. Oxtra LA EU UPD2026
  2. Oxtra LA SmPC2026
  3. Oxtra GE register audit2026
  4. Oxtra 5% official instruction2017
  5. VMD SPC 20242024
  6. MSD tetracyclines2026
  7. Canine LA oxytetracycline PK2001
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
Oxytetracycline200 mg/ml
Formulation Type
Solution
Administration route
Intramuscular
Manufacturer
Fatro von Franken · Argentina
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ოქსტრა ხანგძლივი მოქმედების
№ 1-03/41
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK No
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Terramycin 26.67 mg/ml, Aerosol / spray

Aerosol Spray, oxytetracycline hydrochloride 4 g/150 ml (3.92%), cutaneous spray
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Label-concordant topical treatment of veterinarian-confirmed, oxytetracycline-susceptible superficial bacterial skin lesions in dogs
6.9/10
Situational / acceptable
vetman assessment

Terramycin

Aerosol Spray, oxytetracycline hydrochloride 4 g/150 ml (3.92%), cutaneous spray
Assessed clinical scopeDog · Label-concordant topical treatment of veterinarian-confirmed, oxytetracycline-susceptible superficial bacterial skin lesions in dogs · On the skin
Care settingVeterinary diagnosis and lesion cleaning, followed by clinic or instructed home application with ventilation, lick prevention, fire safety and planned recheck
vetman score 6.9/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, veterinary · Verified on 22 Oct 2026

A credible exact-label topical antibiotic for a narrow, confirmed susceptible superficial lesion—not an empirical all-purpose wound spray. Modern stewardship favours antiseptics first, and absent direct oxytetracycline outcome trials cap efficacy.

Regulatory and scientific credibility8.5/10

The exact 4 g/150 ml product has a current regulator-hosted Romanian authorisation that includes dogs and cats, plus current Georgian registration. A current VMD exact-formulation SPC independently resolves 4 g/150 ml as 3.92% w/w and transparently lists the aerosol composition, although GB authorises only cattle and sheep.

Clinical efficacy5.5/10

The exact label supports susceptible superficial bacterial lesions and modern ISCAID guidance supports topical therapy for canine surface/superficial pyoderma. However, antiseptics are preferred, oxytetracycline has no identified direct canine outcome trial in that review, resistance can be common and deep disease is beyond topical reach.

Safety and tolerability7.0/10

Topical absorption is expected to be negligible and current exact-formulation SPC reports no known target-animal adverse events, but that safety record is from cattle/sheep. Eye exposure, inhalation, hypersensitivity, local irritation, licking and the extremely flammable pressurised aerosol remain meaningful preventable risks.

Clinical practicality6.5/10

The ready-to-use, invertible marker-dye spray covers focal lesions without compounding, but cleaning plus three applications daily until healing is a real home-treatment burden. Ventilation, 18–20 cm distance, lick control, fire safety and rechecks limit convenience compared with suitable antiseptic leave-on options.

Full-course cost-effectiveness-

Current Georgian full-course price and patient-specific can wastage were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Use only for a veterinarian-confirmed superficial bacterial lesion with plausible oxytetracycline susceptibility. It is not a routine disinfectant, healing accelerator or empirical spray for every wound.
  • Perform cytology before antimicrobial treatment. Prefer a suitable effective antiseptic when possible; if response is poor or disease recurs, reassess diagnosis and obtain culture/susceptibility rather than repeating blindly.
  • Do not rely on surface aerosol for deep pyoderma, cellulitis, abscess, devitalised tissue, bite wound, spreading pain/swelling, fever or systemic illness. Examine, drain/debride and add systemic treatment when indicated.
  • Clean the lesion, shake well and apply from about 18–20 cm for 1–2 seconds per lesion three times daily until healed. Recheck the patient; do not continue indefinitely without confirming clinical and cytological response.
  • External cutaneous use only. Do not spray in or near the eyes, face or mucosa and do not allow inhalation. Use in a well-ventilated space and prevent licking or grooming until fully dry.
  • Extremely flammable pressurised aerosol: keep away from flames, cigarettes, sparks, hot surfaces and sunlight. Do not pierce or burn the can, even when empty; store dry below 25°C.
  • Wear impermeable gloves, wash hands and splashes promptly, and avoid contact if hypersensitive to tetracyclines. Stop and reassess local irritation, dermatitis or suspected animal hypersensitivity.
  • Do not apply simultaneously with solutions containing metal salts because tetracyclines can interact with them. Document other topical agents and avoid unassessed mixing on the lesion.
  • Painful lesions may require analgesia and low-stress handling before cleaning or spraying. Poor restraint and close-range spraying increase eye, inhalation and uneven-coverage risk.
  • The exact Romanian dog/cat label supports this regimen, while the current GB label is cattle/sheep only. Do not transfer GB foot-condition schedules or food-animal claims to dogs or cats.
Assessment sources
  1. Terramycin RO label2025
  2. Terramycin VMD SPC2025
  3. ISCAID canine pyoderma 20252025
  4. Canine/feline topical review1996
  5. Merck pyoderma2026
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Label-concordant topical treatment of veterinarian-confirmed, oxytetracycline-susceptible superficial bacterial skin lesions in cats
6.3/10
Situational / acceptable
vetman assessment

Terramycin

Aerosol Spray, oxytetracycline hydrochloride 4 g/150 ml (3.92%), cutaneous spray
Assessed clinical scopeCat · Label-concordant topical treatment of veterinarian-confirmed, oxytetracycline-susceptible superficial bacterial skin lesions in cats · On the skin
Care settingVeterinary diagnosis and lesion cleaning, followed by clinic or instructed home application with ventilation, lick prevention, fire safety and planned recheck
vetman score 6.3/10 Situational / acceptable
Evidence confidence: Low Georgia: Yes, veterinary · Verified on 22 Oct 2026

A legally supported but weakly studied feline option for a narrow susceptible superficial lesion. Aerosol stress, grooming exposure and absence of direct feline outcome data make it a fallback rather than a routine first choice.

Regulatory and scientific credibility8.5/10

The exact 4 g/150 ml product has a current regulator-hosted Romanian authorisation that includes dogs and cats, plus current Georgian registration. A current VMD exact-formulation SPC independently resolves 4 g/150 ml as 3.92% w/w and transparently lists the aerosol composition, although GB authorises only cattle and sheep.

Clinical efficacy4.5/10

The exact Romanian label includes cats and topical therapy is clinically plausible for local superficial infection, but direct feline oxytetracycline-spray outcome evidence was not identified. Feline pyoderma is less well studied, susceptibility is essential and deeper disease or an abscess needs source control and/or systemic therapy.

Safety and tolerability6.5/10

Limited skin absorption is reassuring, but direct feline safety data for repeated whole-course use are sparse. Grooming increases oral exposure risk, aerosol sound/mist can stress the patient, and eye/inhalation exposure, irritation and highly flammable propellant require active control.

Clinical practicality5.5/10

No compounding is needed, but three daily aerosol applications, accurate lesion targeting, ventilation, drying and reliable lick prevention are relatively burdensome in many cats. Noise/mist aversion and facial avoidance can make safe coverage difficult; a suitable non-aerosol antiseptic may be easier.

Full-course cost-effectiveness-

Current Georgian full-course price and patient-specific can wastage were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Use only for a veterinarian-confirmed superficial bacterial lesion with plausible oxytetracycline susceptibility. It is not a routine disinfectant, healing accelerator or empirical spray for every wound.
  • Perform cytology before antimicrobial treatment. Prefer a suitable effective antiseptic when possible; if response is poor or disease recurs, reassess diagnosis and obtain culture/susceptibility rather than repeating blindly.
  • Do not rely on surface aerosol for deep pyoderma, cellulitis, abscess, devitalised tissue, bite wound, spreading pain/swelling, fever or systemic illness. Examine, drain/debride and add systemic treatment when indicated.
  • Clean the lesion, shake well and apply from about 18–20 cm for 1–2 seconds per lesion three times daily until healed. Recheck the patient; do not continue indefinitely without confirming clinical and cytological response.
  • External cutaneous use only. Do not spray in or near the eyes, face or mucosa and do not allow inhalation. Use in a well-ventilated space and prevent licking or grooming until fully dry.
  • Extremely flammable pressurised aerosol: keep away from flames, cigarettes, sparks, hot surfaces and sunlight. Do not pierce or burn the can, even when empty; store dry below 25°C.
  • Wear impermeable gloves, wash hands and splashes promptly, and avoid contact if hypersensitive to tetracyclines. Stop and reassess local irritation, dermatitis or suspected animal hypersensitivity.
  • Do not apply simultaneously with solutions containing metal salts because tetracyclines can interact with them. Document other topical agents and avoid unassessed mixing on the lesion.
  • Cats may resist aerosol noise and mist and then groom the treated site. If safe targeting and reliable lick prevention are not feasible, choose an appropriate non-aerosol alternative rather than forcing repeated exposure.
  • The exact Romanian dog/cat label supports this regimen, while the current GB label is cattle/sheep only. Do not transfer GB foot-condition schedules or food-animal claims to dogs or cats.
Assessment sources
  1. Terramycin RO label2025
  2. Terramycin VMD SPC2025
  3. Canine/feline topical review1996
  4. Merck pyoderma2026
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Oxytetracycline26.67 mg/ml
Formulation Type
Aerosol / spray
Administration route
On the skin
Manufacturer
Zoetis Belgium / IGS Aerosols GmbH · Belgium
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ტერამიცინ აეროზოლ სპრეი
Verified on: 22 Oct 2026
 EU Yes, veterinary
№ RO 140023
Verified on: 22 Oct 2026
 UK Yes, veterinary
№ Vm 42058/5175
Verified on: 22 Oct 2026
 US Not confirmed
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified For a veterinarian-confirmed susceptible superficial bacterial skin lesion: clean the area, shake well, and spray each lesion from about 18–20 cm for 1–2 seconds three times daily until healed, following the exact Romanian dog/cat label. Recheck response and the underlying cause; do not extrapolate this surface regimen to deep, spreading or systemic infection.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗